EHMSG gratefully acknowledges the support of the following companies
RICHEN EUROPE is the European operating branch of the RICHEN GROUP, a major international group of medical device manufacturers with a global commitment. The company specializes in developing the best solutions for patients in the field of gastroenterology. Over the years our R&D department has excelled in the design and development of high-performance safe equipment and reagents for the diagnosis of Helicobacter pylori infection. Since 2015, the Richen Group has been supporting the European Helicobacter & Microbiota Study Group (EHMSG) as Platinum Sponsor.
INFAI is specialized in the transfer of advanced analytical technology in the field of medical diagnostics and the development of innovative pharmaceutical products. The company is a pioneer in the use of stable isotopes in gastroenterology, cardiovascular and inborn metabolic diseases. Helicobacter Test INFAI (HTI) is approved in centralized procedure by EMA first time in all European countries since 1997 and available for routine diagnosis of Helicobacter pylori infection. In the meantime, HTI is registered as medicinal product (medical prescription) in more than 40 countries worldwide.
INFAI's laboratories in Bochum, Germany and in York, England are equipped with state-of-the-art IRMS mass spectrometer and 600 MHz NMR spectrometer which is used to investigate metabolic disorders, cardiovascular diseases and a number of other diseases. These facilities are used for internal research and product development, but are also available for collaborative and contract research. In last 10 years, a range of non-invasive, highly efficient breath tests using stable isotopes has been developed. Gastromotal (13C octanoic acid gastric emptying test) and Pancreo-Lip (13C mixed triglyceride exocrine pancreatic function test) are in preparation for approval by EMA but now available for clinical studies. INFAI is associated with a number of companies in several European countries and outside the Europe. All other developed products of INFAI you can find on our website: https://www.infai.de
Since 1997, INFAI GmbH has been supporting the European Helicobacter & Microbiota Study Group (EHMSG) as Gold Sponsor.
For over 60 years, Dr Falk Pharma GmbH, an independent family company has maintained a strong international reputation for the development and production of products that treat digestive and metabolic diseases. Innovation drives everything we do. As specialists in digestive and metabolic medicine, we bring physicians, scientists, and patients together to develop new and powerful approaches to patient care. We continuously listen to your needs and respond with treatment solutions that provide real improvement to patients’ health and well-being. As a research-based family business with global presence, our aim is to help transform clinical practice, one life-changing discovery at a time. Dr Falk Pharma products have been available since 2006 via Australian distributors. From January 2020, Dr Falk Pharma Australia was established as a direct local presence to provide greater visibility and customer support within this important market. URL: www.drfalkpharma.com.au
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, an investigational potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders.
Voted Best UK Convention Bureau for the last 15 years, Glasgow’s experienced conventions team continuously develops its city wide strategic partnerships, world leading Conference Ambassador Programme and bespoke public engagement activities to support UK, European and international clients with hosting a successful and memorable meeting in Glasgow.